Company: LNAI
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001731122-25-000765
Chunk: 10

Company: Lunai Bioworks Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 10
---
—

(1,225,779
)

Investment in equity securities

(1,464,389
)

—

Cash received from acquisition

—

65,851

Purchase of property and equipment

—

(46,878
)

NET CASH USED IN INVESTING ACTIVITIES

(1,464,389
)

(1,206,806
)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of promissory notes

—

3,645,000

Repayment of finance agreement

(699,588
)

(646,128
)

Proceeds from private placement

2,376,181

3,000,000

Stock subscription payable

3,000,000

—

Proceeds from notes payable

3,527,822

1,710,000

Proceeds from exercise of warrants

—

341,865

NET CASH PROVIDED BY FINANCING ACTIVITIES

8,204,415

8,050,737

Effect of exchange rates on cash

26,020

151,935

NET CHANGE IN CASH

702,535

(1,561,783
)

CASH, BEGINNING OF PERIOD

220,467

1,874,480

CASH, END OF PERIOD
 
$
923,002

$
312,697

SUPPLEMENTAL DISCLOSURES OF CASH FLOW    INFORMATION

Cash paid during the period for:

Interest
 
$
15,995

$
12,692

SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES

Finance agreement entered into in exchange for prepaid assets
 
$
1,018,930

$
906,834

Conversion of note payable for issuance of preferred stock
 
$
—

$
2,000,001

Common shares issued upon acquisition
 
$
—

$
136,001,631

Contingent consideration issued upon acquisition
 
$
—

$
20,557,500

Earn out shares issued in settlement of contingent liability
 
$
—

$
7,775,656

Note payable settled through non-cash exercise of warrants
 
$
—

$
2,000,000

Debt discount related to convertible promissory notes
 
$
24,954

$
—

Debt discount related to notes payable
 
$
—

$
301,841

Cancellation of restricted stock awards
 
$
83

$
—

See accompanying notes to the unaudited condensed consolidated
financial statements.

7